Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros

Medicinas Complementárias
Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Cureus ; 14(9): e29183, 2022 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-36258980

RESUMEN

Background With optimum transfusion and chelation therapy, the survival of ß-thalassemia patients and the incidence of various complications, including renal complications, have improved. Objectives To investigate renal involvement in ß-thalassemia patients using serum and urinary biochemical markers of glomerular and tubular dysfunction. Methods This case-control study included 69 ß-thalassemia major (ß-TM) patients, 23 ß-thalassemia intermedia (ß-TI) patients, and 100 healthy controls, all ranging from 1 to 16 years in age. Blood urea nitrogen (BUN), serum ferritin, serum and urinary levels of creatinine (Cr), uric acid (UA), calcium (Ca), phosphorus (Ph), magnesium (Mg), sodium (Na), and potassium (K), and the urinary albumin/creatinine ratio were evaluated. Results The BUN level and the urinary Na/Cr, K/Cr, Ca/Cr, Mg/Cr, Ph/Cr, albumin/Cr, and UA/Cr ratios were significantly higher in the ß-thalassemia patients than in the controls. In contrast, the serum Na, K, Ca, and Mg levels were significantly lower in the patients (P<0.05). An elevated urinary UA/Cr ratio was found in 61.9% of ß-thalassemia patients, and an elevated urinary Ca/Cr, and urinary albumin/Cr ratio was found in 53.2%. An elevated Na/Cr ratio was found in 41.3%. The serum and urinary renal markers showed no significant differences between patients with ß-TM and ß-TI, except for microscopic hematuria, which was significantly higher in ß-TI patients (34.8%) than in ß-TM patients (13%), P>0.02. At an older age, high serum ferritin levels and deferoxamine therapy were associated with significant tubular and glomerular dysfunction in ß-thalassemia patients. Conclusions Pediatric patients with ß-thalassemia have significantly abnormal tubular and glomerular functions, necessitating early detection and monitoring to prevent/reverse renal function deterioration.

2.
Plant Biol (Stuttg) ; 23 Suppl 1: 152-161, 2021 May.
Artículo en Inglés | MEDLINE | ID: mdl-33176068

RESUMEN

The interaction of mineral nutrients with metals/metalloids and signalling molecules is well known. In the present study, we investigated the effect of phosphorus (P) in mitigation of arsenic (As) stress in mustard (Brassica juncea L.). The study was conducted to investigate potential of 30 mg P·kg-1 soil P supplement (diammonium phosphate) to cope up with the adverse effects of As stress (24 mg As·kg-1 soil) in mustard plants Supplementation of P influenced nitric oxide (NO) generation, which up-regulated proline metabolism, ascorbate-glutathione system and glyoxalase system and alleviated the effects of on photosynthesis and growth. Arsenic stress generated ROS and methylglyoxal content was scavenged through P-mediated NO, and reduced As translocation from roots to leaves. The involvement of NO under P-mediated alleviation of As stress was substantiated with the use of cPTIO (NO biosynthesis inhibitor) and SNP (NO inducer). The reversal of P effects on photosynthesis under As stress with the use of cPTIO emphasized the role of P-mediated NO in mitigation of As stress and protection of photosynthesis The results suggested that P reversed As-induced oxidative stress by modulation of NO formation, which regulated antioxidant machinery. Thus, P-induced regulatory interaction between NO and reversal of As-induced oxidative stress for the protection of photosynthesis may be suggested for sustainable crops.


Asunto(s)
Arsénico , Planta de la Mostaza , Antioxidantes , Arsénico/toxicidad , Suplementos Dietéticos , Óxido Nítrico , Estrés Oxidativo , Fósforo , Fotosíntesis
3.
Eur J Clin Pharmacol ; 71(4): 411-23, 2015 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-25687918

RESUMEN

PURPOSE: Evidence regarding the relationship between red blood cell methotrexate polyglutamate concentration and response to treatment and adverse drug reactions in patients using methotrexate for inflammatory arthropathies is complex and in some respects appears conflicting. Accordingly, we undertook a systematic analysis of available evidence to determine the clinical utility of dosing methotrexate to a target red blood cell methotrexate polyglutamate concentration. METHODS: A systematic literature review was conducted to identify all studies that had reported an association between red blood cell methotrexate polyglutamate concentration and disease activity or adverse drug reactions in users of methotrexate for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis or psoriatic arthritis. RESULTS: No randomised controlled trials were identified. Thirteen studies (ten in patients with rheumatoid arthritis and three in patients with juvenile idiopathic arthritis) were identified. All studies evaluated an association between red blood cell methotrexate polyglutamate concentration and response to treatment, and eight evaluated an association with toxicity. Eight studies identified lower disease activity with at least one higher red blood cell methotrexate polyglutamate concentration, although there was at least moderate potential for bias in all of these studies. Relatively large increases in concentration appeared to be required to produce a meaningful reduction in disease activity. Only one study identified an association between red blood cell methotrexate polyglutamate concentration and methotrexate-induced side effects, although studies were likely underpowered to detect this type of association. CONCLUSIONS: The manner in which data were presented in the included studies had many limitations that hampered its conclusive assessment, but red blood cell methotrexate polyglutamate concentrations appear to be a potentially useful guide to treatment in patients with inflammatory arthropathies, but the specific polyglutamate that should be monitored and how monitoring could be integrated into treat-to-target approaches should be clarified before it can be routinely implemented.


Asunto(s)
Antirreumáticos/metabolismo , Antirreumáticos/uso terapéutico , Artritis/tratamiento farmacológico , Artritis/metabolismo , Eritrocitos/metabolismo , Metotrexato/análogos & derivados , Ácido Poliglutámico/análogos & derivados , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Antirreumáticos/efectos adversos , Niño , Ensayos Clínicos como Asunto , Estudios Transversales , Relación Dosis-Respuesta a Droga , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos/metabolismo , Femenino , Humanos , Masculino , Metotrexato/efectos adversos , Metotrexato/metabolismo , Metotrexato/uso terapéutico , Persona de Mediana Edad , Ácido Poliglutámico/efectos adversos , Ácido Poliglutámico/metabolismo , Ácido Poliglutámico/uso terapéutico , Estudios Prospectivos
4.
Dent J Malays ; 8(2): 39-42, 1985 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-3917006

RESUMEN

Jet injection is a procedure of introducing anaesthetic solution into the tissues without the use of the hypodermic needle. This is accomplished by forcing the solution under high pressure from a minute orifice in the form of a high velocity jet.


Asunto(s)
Anestesia Dental/instrumentación , Anestesia Local/instrumentación , Inyecciones a Chorro , Femenino , Humanos , Masculino
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA